No price range yet · latest SEC filing Jun 4, 2026.
Pinch-zoom for details.
Develops a 'reverse aging' product meant to support cellular health.
Fiscal year
Quarter
Fiscal year
Quarter
| $ | FY2024 | FY2025 | YoY | Q 2026 |
|---|---|---|---|---|
| Revenue | 3.10M | 7.43M | +140% | 2.95M |
| Net result | 651K | 1.59M | +144% | 433K |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | 3.10M | 7.43M | +140% |
| Net result | 651K | 1.59M | +144% |
| $ | Q 2026 |
|---|---|
| Revenue | 2.95M |
| Net result | 433K |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing doesn't set out its strategy in a list we could read.
Source: ROKIT America, Inc.'s Form S-1/A, filed with the SEC on Jun 4, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back